CD274 and neoplasm: Evaluating biomarkers related to immune checkpoint therapy, Corey et al. [22] reported no significant differences in mismatch repair deficiency (dMMR/MSI-H), tumor mutational burden, and PD-L1 expression between the three different molecular subtypes.